The research and development of new drugs is a high-cost, high-stakes industry, and at its center are questions of scientific rigor and ethical standards.
We look at the biomedical ethics of how new drugs get developed for the marketplace. Our guest is Jonathan Kimmelman, associate professor of biomedical ethics at McGill University in Montreal. Kimmelman says there are moral dimensions to drug development, and he studies the risk-benefit balance in the testing and regulating of new pharmaceuticals.
Also in this hour: the Vermont Yankee nuclear power plant. Almost a year after its shutdown, the plant is still spurring debate over safety, spending and the disposal of nuclear waste. We get an update from Rutland Herald reporter Susan Smallheer.
Broadcast live on Mon., Oct. 12, 2015 at noon; rebroadcast at 7 p.m.